Journal: Nature Communications

Article Title: Pla2g7 regulates bone homeostasis via Alox12/12-HETE/Gpr31 signaling axis

doi: 10.1038/s41467-025-66285-8

Figure Lengend Snippet: A The diagrams of bone mass in Pla2g7 f/f , Pla2g7 LysM and Pla2g7 CTSK female mice (scale bar, 1 mm). B , C Trabecular-related parameters in Pla2g7 f/f , Pla2g7 LysM and Pla2g7 CTSK female mice, including BV/TV, Tb.Th, Tb.N and Tb.Sp. n = 6 biologically independent mice per group. D – G HE and TRAP staining of distal of femur, and the histomorphometric parameters of osteoclasts in each group, including Oc.N/BS and Oc.S/BS. The bottom image enlarges the black box labeled region of the middle image. n = 6 biologically independent mice per group. (scale bar, normal images, 200 μm, enlarged images, 100 μm). H , I The expression of serum CTX and PINP using Elisa assays. n = 6 biologically independent mice per group. J The body and hindlimbs length in Pla2g7 f/f , Pla2g7 LysM and Pla2g7 CTSK female mice. K , L The rescued-condition of Pla2g7 conditional knockout in OVX-induced bone loss. OVX is performed at the stage of 12 weeks and the model lasts for 8 weeks (scale bar, 1 mm). M , N Morphological parameters of trabecular bone in each group. n = 6 biologically independent mice per group. Data were showed as mean ± SD. Two-sided Student’s t test ( B , C , E , G , H , I ) was employed to assess the difference between the two groups. Two-way ANOVA ( M , N ) was utilized for multiple comparisons test. Significance: * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001, ns non-significance.

Article Snippet: For serums from patients, Pla2g7 (Cat#E-EL-H2286, Elabscience, China), CTX (Cat#CSB-E11224h, CUSABIO, China) and PINP (Cat#CSB-E11226h, CUSABIO, China) were tested utilizing human ELISA assay kit and the relevance was analyzed using Pearson correlation coefficient.

Techniques: Staining, Labeling, Expressing, Enzyme-linked Immunosorbent Assay, Knock-Out

Journal: BMC Cardiovascular Disorders

Article Title: Increased ratio of sST2/LVMI predicted cardiovascular mortality and heart failure rehospitalization in heart failure with reduced ejection fraction patients: a prospective cohort study

doi: 10.1186/s12872-021-02191-3

Figure Lengend Snippet: Baseline characteristics of HFrEF patients

Article Snippet: The characteristics of the assays were as follows: sST2 ELISA (Critical Diagnostics, San Diego, CA, USA, Catalog No. BC-1065E): average intra-assay coefficient of variation (CV) of 5.1%, detection limit of 1.8 ng/mL; PIIINP ELISA (MyBioSource, San Diego, CA, USA; Catalog No. MBS703383): intra-and inter-assay CV of less than 10%, detection range 0.125–8 ng/mL; PICP ELISA (Elabscience, Wuhan, China; Catalog No. E-EL-H6030): intra- and inter-assay CV less than 10%, detection range 0.78 to 50 ng/mL.

Techniques: Functional Assay

Journal: Frontiers in Nutrition

Article Title: Changes in Intestinal Flora Structure and Metabolites Are Associated With Myocardial Fibrosis in Patients With Persistent Atrial Fibrillation

doi: 10.3389/fnut.2021.702085

Figure Lengend Snippet: Serum levels of myocardial fibrosis markers. (A) Levels of CTX-I in serum. (B) Levels of PICP in serum. (C) Levels of PIIINP in serum. (D) Levels of FGF-23 in serum. (E) Levels of TGF-β1 in serum. (F) Levels of PIIINP in serum. * p < 0.05 vs. control group. CTX-I, carboxy-terminal telopeptide of type I collagen; PICP, propeptide of type I procollagen; PIIINP, procollagen III N-terminal propeptide; FGF-23, fibroblast growth factor-23; TGF-β1, transforming growth factor-beta 1.

Article Snippet: According to the manufacturer's instructions, ELISA was performed using the following kits: CTX-I (CSB-E11224h, CUSABIO BIOTECH, Wuhan), PICP (CSB-E08079h, CUSABIO BIOTECH, Wuhan), PIIINP (JL19037, Jianglai, China), FGF-23 (CSB-E10113h, CUSABIO BIOTECH, Wuhan), and TGF-β1 (CSB-E04725h, CUSABIO BIOTECH, Wuhan).

Techniques: Control

Journal: Journal of the Endocrine Society

Article Title: Subclinically low BMD in young men is associated with compromised bone microarchitecture and lower lean mass

doi: 10.1210/jendso/bvag003

Figure Lengend Snippet: Biomarkers. Fig. 1 depicts all assessed biomarker concentrations. The total hip, femoral neck, or lumbar spine (Lower) group is depicted in black filled circles, while the control (Con) group is in clear squares. A, P1NP (pg/mL); B, alkaline phosphatase (ALP) (pg/mL); C, tartrate-resistant acid phosphatase 5b (TRAP5b) (U/L); D, sclerostin (pmol/L); E, β C-terminal cross-linked telopeptide of type I collagen (βCTX) (pmol/L); F, testosterone (ng/mL); G, estradiol (pg/mL); H, parathyroid hormone (PTH) (pg/mL); I, insulin-like growth factor-1 (IGF-1) (ng/mL); J, insulin-like growth factor-1 binding protein 5 (IGFBP-5) (ng/mL).

Article Snippet: Commercially available enzyme-linked immunosorbent assays were used to determine circulating concentrations of serum procollagen type I N-terminal propeptide (PINP; Novus catalog No. NBP2-76465, RRID:AB_3720306, 1:200 dilution, CV 5.3%, sensitivity 9.4 pg/mL), alkaline phosphatase (ALP; Novus catalog No. NBP2-68197, RRID:AB_3720307, CV 6.0%, sensitivity 46.9 pg/mL), tartrate-resistant acid phosphatase 5b (TRAP5b; Immunodiagnostic Systems catalog No. SB-TR201A, RRID:AB_3095995, CV 4.7%, sensitivity 0.4 U/L), sclerostin (Biomedica catalog No. BI-20492, RRID:AB_2894889, CV 6.4%, sensitivity 3.2 pmol/L), testosterone (Alpco Diagnostics catalog No. 11-TESHU-E01, RRID:AB_3720308, CV 4.2%, sensitivity 0.02 ng/mL), estradiol (Alpco Diagnostics catalog No. 11-ESTHU-E01, RRID:AB_2756385, CV 7.6%, sensitivity 10 pg/mL), insulin like growth factor-1 (IGF-1; Alpco Diagnostics catalog No. 22-IGFHU-E01, RRID:AB_2923276, 1:20 dilution, average CV 3.3%, assay sensitivity 9.4 pg/mL), IGF binding protein-5 (IGFBP-5; R and D Systems catalog No. DY875, RRID:AB_3720311, 3× dilution, CV 2.7%), parathyroid hormone (PTH; (Alpco Diagnostics catalog No. 21-IPTHU-E01, RRID:AB_2943035), CV 7.3%, sensitivity 1.6 pg/mL), and plasma β C-terminal cross-linked telopeptide of type I collagen (βCTX; Immunodiagnostic Systems catalog No. IS-3000N, RRID:AB_3720313, CV 6.2%, sensitivity 3.2 pmol/L).

Techniques: Biomarker Discovery, Control, Binding Assay